| Code | CSB-RA001898MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to dezamizumab, targeting amyloid P component, serum (APCS), also known as serum amyloid P component (SAP). APCS is a highly conserved plasma glycoprotein and a universal constituent of amyloid deposits across all types of systemic amyloidosis. This pentraxin family member binds to amyloid fibrils in a calcium-dependent manner, where it stabilizes deposits and protects them from proteolytic degradation. APCS plays a critical role in the pathogenesis of amyloidosis, including AL amyloidosis, AA amyloidosis, and transthyretin amyloidosis, as well as contributing to Alzheimer's disease pathology through its association with beta-amyloid plaques.
Dezamizumab represents a therapeutic approach designed to deplete circulating SAP and remove it from amyloid deposits, potentially facilitating fibril clearance by the immune system. This biosimilar antibody serves as a valuable research tool for investigating amyloid formation mechanisms, SAP-amyloid interactions, and potential therapeutic interventions in amyloid-related diseases. It supports studies in protein misfolding disorders, innate immunity, and degenerative disease pathology.
There are currently no reviews for this product.